ReviewFrontiers in genetics2026
Human papillomavirus infection and atherosclerotic cardiovascular disease: a comprehensive review of epidemiological evidence, molecular mechanisms, and vaccination-mediated protection.
Review in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging epidemiological evidence indicates that persistent infection with high-risk human papillomavirus (HPV) genotypes is independently associated with elevated atherosclerotic cardiovascular disease (CVD) risk, challenging traditional paradigms of cardiovascular risk assessment. This review synthesises current observational data on this association, explores the potential inflammatory, immune, and metabolic mechanisms that may connect HPV to atherogenesis, and evaluates the emerging evidence for cardiovascular protection conferred by HPV vaccination. Large cohort studies report significantly elevated risks of myocardial infarction, stroke, and cardiovascular mortality among women with high-risk HPV infection, independent of conventional risk factors. Mechanistically, HPV oncoproteins E6 and E7 activate nuclear factor-κB (NF-κB)-mediated inflammatory cascades, induce endothelial dysfunction through p53 degradation, and establish a pro-atherogenic systemic inflammatory milieu characterized by elevated interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). Preliminary retrospective analyses further indicate that HPV vaccination is linked to a reduced incidence of new-onset cardiovascular and cerebrovascular events, although healthy-user bias and residual confounding limit causal interpretation. Despite these intriguing signals, the bulk of evidence is derived from cross-sectional and retrospective designs, and the direct demonstration of a causal link remains absent. We discuss critical methodological challenges-including confounding by sexual behaviour, socioeconomic status, and co-infections-and outline a roadmap for prospective cohort studies, mechanistic investigations, and rigorous risk-stratification research. Clarifying the nature of the HPV-CVD relationship could open novel avenues for the primary prevention of atherosclerotic disease through vaccination programmes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.